Clinical Trial Progress Update The analytic treatment interruption (ATI) protocol is generating important immunological data. We are currently gathering and analyzing data from five out of the seven clinical… [Read More]
NEWSLETTER VOLUME 14
Exciting HIV Clinical Trial Update American Gene Technologies® HIV Cure Clinical Trial Enters Critical Phase: Withdrawing Participants from Antiretrovirals. “This is a critical step in our mission to cure HIV… [Read More]
NEWSLETTER VOLUME 13
HIV Program Treatment Withdrawal Safety and efficacy blood markers have been recorded in the Phase 1 human trial for AGT’s HIV cure. We expect the antiretroviral treatment withdrawal studies to… [Read More]
NEWSLETTER VOLUME 12
HIV Program Update Five for Five! American Gene Technologies (AGT) announced that it has reached another important milestone in its HIV cure program. Five participants were treated with AGT103-T and… [Read More]
NEWSLETTER VOLUME 11
HIV Program Update Enrolled First Cohort Since our last Newsletter, AGT has enrolled its first cohort of six participants in its Phase 1 study of AGT103-T against HIV. Updates on… [Read More]
NEWSLETTER VOLUME 10
We’ve achieved a number of significant milestones this quarter, including the Food and Drug Administration (FDA) clearance to begin Phase 1 of our HIV cure program. The excitement hasn’t only been… [Read More]
NEWSLETTER VOLUME 9
FDA Progress The Path to the Clinic For the HIV Cure This month, AGT saw tremendous progress with the FDA. FDA time and attention to our project has seemed to… [Read More]
NEWSLETTER 2020 EDITION
A STELLAR 2019 Has Positioned AGT For A SPECTACULAR 2020. I wanted to take a moment to sum up a great year of progress and success at AGT and to talk about… [Read More]
NEWSLETTER VOLUME 8
AGT’s HIV cure program is nearing a major milestone: Investigational New Drug (IND) submission. The IND is the key document that reports the safety data the FDA requires prior to… [Read More]
NEWSLETTER VOLUME 7
In wrapping up the year, AGT was proud to be featured as a State of Maryland “Success Story” for its growth in Maryland and achievements in the gene and cell… [Read More]
NEWSLETTER VOLUME 6
AGT’s progress over the first half of 2018 has been tremendous: six patents granted, major advances in all of its key projects: HIV, PKU and immuno-oncology, substantial momentum on social media with constant activity… [Read More]
NEWSLETTER VOLUME 5
AGT is in position for key milestones and success in 2018. 2017 brought attention to the industry and particularly to AGT. We raised nearly $8M (approximately double the previous year),… [Read More]
